Authors: Wenjun Hao, Siwen Chen, Hua Chao, Zihao Li, Hao Yang, Dongying Chen, Sifang Li, Shuai Zhang, Jingyu Zhang, Jianru Wang, Zemin Li, Xiang Li, Zhongping Zhan, Tangming Guan, Yiwen Zhang, Wende Li, Hui Liu
Published: 2025-03-17
Source: Full article
AbstractPathological new bone formation is the main cause of disability in ankylosing spondylitis (AS), and so far, it lacks a targeted therapy. Macrophages are central orchestrators of inflammation progression and tissue remodeling, but their contribution to pathological new bone formation has largely not been explored. Here, it is identified that TREM2+ macrophages predominated within the sites of new bone formation and adjacent to osteogenic precursor cells. In vivo, both depletion of macrophages and knockout of Trem2 significantly reduced pathological new bone formation in a collagen antibody‐induced arthritis (CAIA) model. Specifically, TREM2+ macrophages promoted osteogenic differentiation of ligament‐derived progenitor cells (LDPCs) by secreting CREG1, a secretory glycoprotein involved in cell differentiation and normal physiology. CREG1‐IGF2R‐PI3K‐AKT signaling pathway is involved in TREM2+ macrophage‐mediated pathological new bone formation. In addition, it is found that IL‐33 promoted TREM2+ macrophage differentiation through phosphorylation of STAT6. Targeting the above signalings alleviated new bone formation in the CAIA model. The findings highlight the critical role of IL‐33‐induced TREM2+ macrophages in pathological new bone formation and provide potential therapeutic targets for halting spinal ankylosis in AS.